A Phase 3 interventional study of RC-28E and Aflibercept in Diabetic Macular Edema, sponsored by RemeGen Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-05.
Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.
Among the 72 studies in Macular Edema with a site in China, this one is the 15th largest by planned enrollment of the 65 interventional ones that give a count, is one of 11 that started in 2023, is one of 25 in phase 3, reaches primary completion later than 10 of the 21 other live ones, and was the 49th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Boehringer Ingelheim · Sites in China, United States, Czechia and 6 more countries
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 12 · Phase 3 26 · Phase 4 9
First in 2003; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 316 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 140 across the 65 interventional studies, 110 across the 7 observational. Of the 38 that completed or were terminated, 13 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 72 have an industry lead sponsor. The 10 most frequent:
RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.
RemeGen Co., Ltd. has 3 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Edema with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07515079Phase 3Bio-Thera SolutionsEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | 2027-04-30 |
| NCT07019896Peking Union Medical College HospitalMinimal Vitrectomy Surgery for Epiretinal Membrane | 2026-11-30 |
| NCT06548568AbbVieA Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China | 2027-04 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
| NCT07362927Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Macular Edema with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The study eye must meet the following requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RC-28E 2.0 mg will be initially intravitreal injected (IVT) 5 times at 4 week intervals from week 0 to week 16, then every 8 weeks until week 48.
Biological: RC-28E
Aflibercept 2.0mg will be received IVT once every 4 weeks for 5 consecutive times from week 0 to week 16, then once every 8 weeks till week 48.
Biological: Aflibercept
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
Change from baseline in BCVA at Week 52
BCVA=best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a starting distance of 4 meters
Time frame: Baseline, week 52
Average change in BCVA from baseline over the period week 40 through week 52
For each subject, this endpoint is defined as the average of the changes from baseline to weeks 40, 44, 48 and 52
Time frame: Baseline, weeks 40, 44, 48 and 52
Change from baseline in BCVA over time
BCVA will be assessed at each visit
Time frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Proportion of patients gaining >15, >10, >5, or >0 letters in BCVA from baseline at Week 52
Proportion of patients of gaining 4 types of letter counting in BCVA, respectively
Time frame: Baseline, week 52
Proportion of patients avoiding a loss of >15, >10, >5, or >0 letters in BCVA from baseline at Week 52
Proportion of patients of reducing 4 types of letter counting in BCVA, respectively
Time frame: Baseline, week 52
Change from baseline in CST at Week 52
CST=central subfield thickness
Time frame: Baseline, week 52
Mean change from baseline in CST over a period of week 40 through week 52
CST=central subfield thickness
Time frame: Baseline, weeks 40, 44, 48 and 52.
Change from baseline in CST over time
The change of CST will be assessed from baseline to 52 weeks by every 4 week intervals
Time frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Proportion of patients with absence of intraretinal fluid at Week 52
Proportion of patients whose intraretinal fluid are completely improved
Time frame: Baseline, week 52
Proportion of patients with absence of subretinal fluid at Week 52
Proportion of patients whose subretinal fluid are completely improved
Time frame: Baseline, week 52
Proportion of patients with absence of intraretinal fluid and subretinal fluid at Week 52
Proportion of patients whose intraretinal fluid and subretinal fluid are both completely improved
Time frame: Baseline, week 52
Proportion of patients with a >2-step or>3-step DRS worsening from baseline on ETDRS DRSS at Week 52
DRSS=Diabetic Retinopathy Severity Scale
Time frame: Baseline, week 52
Proportion of patients who develop new PDR or high risk PDR at Week 52
PDR=proliferative diabetic retinopathy
Time frame: Baseline, week 52
Incidence and severity of ocular adverse events and non-ocular adverse events
during the study
Time frame: 0~52 weeks
Plasma concentration of RC28-E over time
during the study
Time frame: Baseline, weeks 16, 36 and 48
Presence of ADAs during the study relative to the presence of ADAs at baseline
during the study
Time frame: Baseline, weeks 12, 24, 36 and 52
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 36 months is above that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RC28-E protein